An observational study in Pneumocystis Jirovecii Infection, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Pneumonia with a site in France — 18 open to participants now, 20 under way, 3 of them phase 3. Pneumonia · France.
Among the 138 studies in Pneumonia with a site in France, this one is the 24th largest by planned enrollment of the 56 observational ones that give a count, is one of 3 that started in 2023, is one of 56 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 120th registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →18 of the 138 studies in Pneumonia with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Sud Francilien · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
University Hospital, Caen · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 32 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 255 across 537 observational studies indexed under Pneumonia.
Median enrollment 161 across the 79 interventional studies, 227 across the 56 observational. Of the 99 that completed or were terminated, 14 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 138 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 2 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
3 of the studies in Pneumonia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07439146University Hospital, Clermont-FerrandRisk of Pneumonia in Intubated Patients in Emergency Situations | 2026-12-31 |
| NCT06916481Assistance Publique - Hôpitaux de ParisDefinition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 138 studies in Pneumonia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients.
Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years.
Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii
Adult patients with a positive respiratory sample for P. jirovecii
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Survival at six weeks and three months after infection
Time frame: six weeks after infection
Started Jan 2023 (actual). Primary completion is estimated for Aug 2025, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →